drugset / Trial / NCT03928275
The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma
RandomizedSequentialOpen-labelTreatment
Summary
The investigators aim to include 100 local participants over the next 5 years in a two-stage sequential randomized interventional study of intralesional Interleukin-2 (IL-2) and Bacillus Calmette Guerin (BCG) to assess the utility of treating cutaneous metastatic melanoma (CMM).
Timeline
- Start
- 2021-12-01
- Primary completion
- 2022-09-01
- Completion
- 2022-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bacillus Calmette-Guérin | Vaccine | 3.2e+06 unknown | Other |
| Subject | aldesleukin | Protein / enzyme biologic | 500000 iu | Other |